(19)
(11)EP 2 702 033 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
08.06.2016 Bulletin 2016/23

(21)Application number: 12720465.9

(22)Date of filing:  27.04.2012
(51)International Patent Classification (IPC): 
C07C 55/10(2006.01)
C07C 69/86(2006.01)
C07C 229/12(2006.01)
A61K 31/616(2006.01)
A61K 31/197(2006.01)
A61P 9/00(2006.01)
C07C 57/15(2006.01)
C07C 227/18(2006.01)
C07D 239/557(2006.01)
A61K 31/205(2006.01)
A61K 31/513(2006.01)
(86)International application number:
PCT/EP2012/057806
(87)International publication number:
WO 2012/146736 (01.11.2012 Gazette  2012/44)

(54)

USE OF 3-CARBOXY-N-ETHYL-N,N-DIMETHYLPROPAN-1-AMINIUM SALTS IN THE TREATMENT OF CARDIOVASCULAR DISEASE

VERWENDUNG VON 3-CARBOXY-N-ETHYL-N,N-DIMETHYLPROPAN-1-AMINIUMSALZEN BEI DER BEHANDLUNG VON KARDIOVASKULÄREN ERKRANKUNGEN

UTILISATION DE SELS DE 3-CARBOXY-N-ETHYL-N,N-DIMETHYLPROPAN-1-AMINIUM POUR TRAITER UNE MALADIE CARDIOVASCULAIRE


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 27.04.2011 EP 11163839
27.04.2011 EP 11163841
27.04.2011 EP 11163840
27.04.2011 EP 11163872
27.04.2011 EP 11163871

(43)Date of publication of application:
05.03.2014 Bulletin 2014/10

(73)Proprietor: Grindeks, a joint stock company
1057 Riga (LV)

(72)Inventors:
  • STONANS, Ilmars
    LV-1057 Riga (LV)
  • KALVINS, Ivars
    LV-5050 Ikskile (LV)
  • DAMBROVA, Maija
    LV-1006 Riga (LV)
  • LIEPINS, Edgars
    LV-1012 Riga (LV)
  • GRINBERGA, Solveiga
    LV-2169 Salaspils (LV)
  • KUKA, Janis
    LV-3004 Jelgava (LV)
  • LOLA, Daina
    LV-1039 Riga (LV)
  • LOZA, Einars
    LV-2010 Jurmala (LV)
  • PUGOVICS, Osvalds
    LV-1004 Riga (LV)
  • VILSKERSTS, Reinis
    LV-1064 Riga (LV)


(56)References cited: : 
EP-A1- 2 070 529
WO-A1-2010/149654
WO-A1-2011/048201
WO-A1-97/06794
WO-A1-2010/151095
US-A- 5 965 615
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


    Description

    Technical Field



    [0001] The present invention relates to new compound 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt, and to a method of preparation thereof having general formula
    wherein R1 is -



    [0002] The present invention relates also to a 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt selected from 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate, 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate for use in the treatment of cardiovascular disease.

    Background Art



    [0003] Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vesels.

    [0004] An estimated 16.7 million - or 29.2% of total global deaths - result from the various forms of cardiovascular disease (CVD).

    [0005] Myocardial infarction (heart attack) is a serious result of coronary artery disease. Myocardial infarction (MI) is the irreversible necrosis of heart muscle secondary to prolonged ischemia. A heart attack or myocardial infarction is a medical emergency in which the supply of blood to the heart is suddenly and severely reduced or cut off, causing the muscle to die from lack of oxygen. More than 1.1 million people experience a heart attack (myocardial infarction) each year, and for many of them, the heart attack is their first symptom of coronary artery disease. A heart attack may be severe enough to cause death or it may be silent. As many as one out of every five people have only mild symptoms or none at all, and the heart attack may only be discovered by routine electrocardiography done some time later.

    [0006] A heart attack (myocardial infarction) is usually caused by a blood clot that blocks an artery of the heart. The artery has often already been narrowed by fatty deposits on its walls. These deposits can tear or break open, reducing the flow of blood and releasing substances that make the platelets of the blood sticky and more likely to form clots. Sometimes a clot forms inside the heart itself, then breaks away and gets stuck in an artery that feeds the heart. A spasm in one of these arteries causes the blood flow to stop.

    [0007] γ-Butyrobetaine, from which the mammalian organism synthesises carnitine, was primarily characterised as a toxic substance
    which accelerates respiration, causes salivation and lacrimation, pupil dilation, vasoconstriction and heart stop in diastole LINNEWEH, W. Gamma-Butyrobetain, Crotonbetain und Carnitin im tierischen Stoffwechsel. Hoppe-Seylers Zeitschrift für physiologische Chemie. 1929, vol.181, p.42-53. At the same time, in later papers other authors ascertained that γ-butyrobetaine is extremely low toxic (LD50>7000 mg/kg, s.c.) ROTZSCH, W. Iber die Toxizitat des Carnitins und einiger verwandter Stoffe. Acta biol. med. germ.. 1959, vol.3, p.28-36.

    [0008] In the literature data on nonsubstututed γ-butyrobetaine cardiovascular effects are missed, thought it was reported HOSEIN, E.A. Pharmacological actions of y-butyrobetaine. Nature. 1959, vol. 183, p.328-329. that γ-butyrobetaine is a substance similar to acetyl choline with a prolonged action. However, later the same authors reported that by an error the experiments involved, instead of y-butyrobetaine, its methyl esther which in fact possesses cholinergic properties. Contrary to the former γ-butyrobetaine was characterised as a pharmacologically inert substance HOSEIN, E.A. Isolation and probable functions of betaine esters in brain metabolism. Nature. 1960, vol.187, p.321-322.

    [0009] As structurally related compounds to 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts are disclosed in:

    [0010] 3- (2,2,2-Trimethylhydrazinium) propionate dihydrate is known as compound with cardioprotective properties (this substance being known under its International Nonproprietary Name of Meldonium). 3- (2,2,2-Trimethylhydrazinium) propionate is disclosed in US 4481218 (INST ORGANICHESKOGO SINTEZA) 06.11.1984 as well in US 4451485 A (INSTITU ORCH SINTEZA AKADEMII) 29.05.1984.

    [0011] It is well known that 3- (2, 2,2-trimethylhydrazinium) propionate as dihydrate is widely used for controlling carnitine and gamma-butyrobetaine concentration ratio and consequently the speed of fatty acid beta-oxidation in the body DAMBROVA M., LIEPINSH E., KALVINSH I. I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends in Cardiovascular Medicine,. 2002, vol. 12, no.6, p.275-279.

    [0012] Due to these properties, Meldonium is extensively applied in medicine as an anti-ischemic, stress-protective and cardioprotective drug in treating various cardiovascular diseases and other pathologies involving tissue ischemia KARPOV R.S., KOSHELSKAYA O.A., VRUBLEVSKY A.V., SOKOLOV A.A., TEPLYAKOV A.T., SKARDA I., DZERVE V., KLINTSARE D., VITOLS A., KALNINS U., KALVINSH I., MATVEYA L., URBANE D. Clinical Efficacy and Safety of Mildronate in Patients With Ischemic Heart Disease and Chronic Heart Failure. Kardiologiya. 2000, no.6, p.69-74. In the treatment of cardiovascular diseases the mechanism of action of 3-(2,2,2-trimethylhydrazinium)propionate based on limitation of carnitine biosynthesis rate and related long-chain fatty acid transport limitation through mitochondria membranes SIMKHOVICH B.Z., SHUTENKO Z.V., MEIRENA D.V., KHAGI K.B., MEZHAPUKE R.J., MOLODCHINA T.N., KALVINS I.J., LUKEVICS E.

    [0013] 3-(2,2,2,-Trimethylhydrazinium)propionate (THP) - a novel gamma-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochemical Pharmacology. 1988, vol.37, p.195-202. , KIRIMOTO T., ASAKA N., NAKANO M., TAJIMA K., MIYAKE H., MATSUURA N. Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. European Journal of Pharmacology. 2000, vol.395, no.3, p.217-224.

    Summary of invention



    [0014] As it was known what Meldonium dihydrate has cardioprotective effect and its salt Meldonium orotate is used for the treatment of cardiovascular diseases EP2070529 B (GRINDEKS JSC) 12.10.2011 ; however there are no data that γ-butyrobetaine itself has pronounced cardioprotective effect. In the patent EP 0845986 B (KALVINSH IVARS, VEVERIS MARIS) 02.04.2003 is disclosed pharmaceutical composition of Meldonium dihydrate and γ-butyrobetaine for use in the treatment of cardiovascular diseases.

    [0015] An object of the present invention is to provide a compound, which has pronounced cardioprotective effect.

    [0016] The above-mentioned object is attained by providing new compounds 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts (compound of formula 4), which has similar structure to Meldonium or γ-butyrobetaine.
    wherein R1 is -



    [0017] To our surprise 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts posses pronounced cardioprotective effect and are more effective as Meldonium dihydrate in vivo myocardial infarction models, due to this property 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts may be used in medicine. 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts can be use as a solution for injection.

    [0018] The following object of the present invention is a method of preparation of said compound of formula 4.

    [0019] There is disclosed process, which can be used in purpose to prepare target compound 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts of formula 4, see scheme bellow.



    [0020] Process for preparing 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt of formula 4 involves the following process steps:
    1. a) adding N,N-dimethylethylamine to ethyl 4-bromobutanoate (1) in appropriate solvent to obtain 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide (2);
    2. b) passing 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide (2) through ion exchange resin column to obtain 4-[ethyl(dimethyl)ammonio] butanoate (3);
    3. c) adding acid which is selected from (E)-butenedioic acid (4 a), 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid monohydrate (4 b ) or phosphoric acid (4 c) to 4-[ethyl(dimethyl)ammonio] butanoate (3) in appropriate solvent to obtain 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt (4).

    Description of embodiments



    [0021] The present invention will be described in more detail by referring to the following non-limiting examples.

    Preparation of 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide (2)


    Procedure A



    [0022] To a solution of ethyl 4-bromobutanoate (1) (20.0 g, 102.5 mmol) in acetonitrile (70 ml) N,N-dimethylethylamine (15 ml, 139 mmol) was added and stirred at ambient temperature for 3 days. The reaction mixture was evaporated, the residue was triturated with acetone (50 ml), filtered, washed with ether, and dried to afford 26.051 g (94.8%) of the 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide. LCMS (ESI+, m/z): [M-Br]+ 188, purity 98.9%.
    1H NMR (CDCl3, HMDSO) δ: 1.26 (t, J=7.2 Hz, 3H); 1.44 (t, J=7.4 Hz, 3H); 2.00-2.11 (m, 2H); 2.52 (t, J=6.6 Hz, 2H); 3.40 (s, 6H); 3.64-3.73 (m, 2H); 3.69 (q, J=7.4 Hz, 2H); 4.14 (q, J=7.2 Hz, 2H).

    Procedure B



    [0023] To a solution of ethyl 4-bromobutanoate (1) (19.5 g, 100 mmol) in acetone (70 ml) N,N-dimethylethylamine (15 ml, 139 mmol) was added and stirred at ambient temperature for 3 days. The reaction mixture was filtered; the solid material was washed with an acetone, ether, and dried to afford 24.19 g (90.2%) of the title compound 2. The filtrate was evaporated; the residue (2.147 g) was triturated with ether and dried to give an extra batch (0.962 g, 3.6%) of the product 2 of the same quality as the main portion. The evaporation of the ether washings allowed recovering 0.956 g (4.9 mmol, 4.9%) of the starting material 1. 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide: LCMS (ESI+, m/z): [M-Br]+ 188, purity 98.4%.
    1H NMR (CDCl3, HMDSO) δ: 1.26 (t, J=7.2 Hz, 3H); 1.44 (t, J=7.4 Hz, 3H); 2.00-2.11 (m, 2H); 2.52 (t, J=6.6 Hz, 2H); 3.40 (s, 6H); 3.64-3.73 (m, 2H); 3.69 (q, J=7.4 Hz, 2H); 4.14 (q, J=1.2 Hz, 2H).

    Preparation of 4-[ethyl(dimethyl)ammonio]butanoate (3)


    A solution of 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide (2)



    [0024] (12.00 g, 44.7 mmol) in water (10 ml) was passed through Amberlite ® IRA-410 (OH) ion exchange resin column (250 ml) eluting slowly (ca. 10 drops/min) with ethanol (TLC control). The eluate was evaporated and the residue (12 g) was dissolved in water (50 ml). To this solution DOWEX® 50WX8 ion exchange resin (5 g) was added and stirred at ambient temperature for 0.5 h. The reaction mixture was filtered through celite (1 cm) and the eluate was evaporated. The residue was azeotropically dried with isopropanol, acetonitrile, and acetone. The obtained solid was triturated with acetone (10 ml) and the mixture was kept at 0°C for 2 h. The precipitate was filtered and dried in vacuo over P2O5 to give 4.65 g (65%) of the 4-[ethyl(dimethyl)ammonio]butanoate (3).
    (DMSO-d6, HMDSO) δ: 1.24 (t, J=7.3 Hz, 3H); 1.66-1.76 (m, 2H); 1.81 (t, J=6.4 Hz, 2H); 2.95 (s, 6H); 3.16-3.23 (m, 2H); 3.29 (q, J=7.3 Hz, 2H). LCMS (ESI+, mlz): 160 [M+H]+.

    [0025] Anal. Calc. for C8H17NO2 1.55 H2O: C 51.34; H 10.82; N 7.48.

    [0026] Found: C 51.36, H 11.40, N 7.34.

    Preparation of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate (4 a)



    [0027] To a solution of 4-[ethyl(dimethyl)ammonio]butanoate (3) (2.0 g, 12.56 mmol) in anh. ethanol (10 ml) a hot (60°C) solution of (E)-butenedioic acid (1.46 g, 12.56 mmol) in ethanol (50 ml) was added. The reaction mixture was allowed to stand at ambient temperature for 2 h, the precipitated crystals were filtered and dried over P2O5 to give 2.98 g (85%) of the 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate. M.p. 122-123°C.
    1H-NMR (D2O, DSS) δ: 1.36 (tt, J=1.9, 7.3 Hz, 3H); 2.06 (m, 2H); 2.49 (t, J=7.1 Hz, 2H); 3.06 (s, 6H); 3.31 (m, 2H); 3.40 (q, J=7.3 Hz, 2H); 6.75 (s, 1.9H, CH=CH). LCMS ESI+ (m/z): 160 [M+H]+. Titration assays: water content (Fisher) 0.13%, betaine content (HClO4) 93.0%, (E)-butenedioic acid content 46.1%.
    Anal. Calc. for C8H17NO2. 1.2 C4H4O4 (46.7%): C 51.50, H 7.36, N 4.69.
    Found: C 51.52, H 7.35, N 4.61.

    Preparation of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate (4 b)



    [0028] To a solution of 4-[ethyl(dimethyl)ammonio]butanoate (3) (2.0 g, 12.56 mmol) in isopropanol (100 ml) 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid monohydrate (2.187 g, 12.56 mmol) was added and the reaction mixture was heated to reflux until all the carboxylic acid dissolved. The reaction mixture was allowed to cool to ambient temperature, the precipitated crystals were filtered, washed with isopropanol (5 ml) and diethyl ether (20 ml), and dried over P2O5 to give 3.238 g (97.4%) of the 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate. M.p. 150.7°C.
    1H-NMR (D2O, DSS) δ: 1.36 (tt, J=2.0, 7.3 Hz, 3H); 2.05 (m, 2H); 2.47 (t, J=7.0 Hz, 2H); 3.07 (s, 6H); 3.31 (m, 2H); 3.41 (q, J=7.3 Hz, 2H); 6.20 (s, 1 H, C=CH). LCMS ESI+ (m/z): 160 [M+H]+.
    Anal. Calc. for C8H17NO2 · C5H4N204 (49.5%): C 49.52, H 6.71, N 13.33.
    Found: C 49.59, H 6.69, N 13.26.

    Preparation of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate (4 c)



    [0029] To a solution of 4-[ethyl(dimethyl)ammonio]butanoate (3) (6.4 g, 40 mmol) in water (10 ml) a solution of 85% aq. H3PO4 (4.73 g, 40 mmol) in acetone (10 ml) was added and the resulting solution was stirred at ambient temperature for 10 min. The reaction mixture was evaporated and azeotropically dried several times with acetone by rotary evaporator at 45°C. The obtained white crystalline substance was dried over P2O5 to give 9.82 g (95%) of the 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate. M.p. 110-135°C.
    1H-NMR (D2O, DSS) δ: 1.36 (tt, J=1.8, 7.3 Hz, 3H); 2.06 (m, 2H); 2.50 (t, J=7.0 Hz, 2H); 3.06 (s, 6H); 3.32 (m, 2H); 3.41 (q, J=7.3 Hz, 2H). LCMS ESI+ (m/z): 160 [M+H]+. Titration assays: water content (Fisher) 0.356%, betaine content (HClO4) - 95.682%.
    Anal. Calc. for C8H17NO2 · 0.052 H2O (0.356%) · 1.07 H3PO4 (39.6%): C 36.26; H 7.73; N 5.29.

    Found: C 36.20, H 7.72, N 5.11.



    [0030] The purity of the obtained 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate was increased by crystallization from methanol. Thus, the 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate (6.9 g) was crystallized from methanol (40 ml) to afford 5.326 g (77%) of the purified 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate with m.p. 139°C. Calc. for C8H17NO2 · H3PO4 (38.1 %): C 37.36; H 7.84; N 5.45.
    Found: C 37.52, H 7.85, N 5.39

    Cardioprotective activity



    [0031] Fifty male, 10 weeks old Wistar rats weighing 200-250 g were housed under standard conditions (21-23°C, 12 h light-dark cycle) with unlimited access to food (R3 diet, Lactamin AB, Sweden) and water.
    Rats were adapted to local conditions for two weeks before the start of treatment. Meldonium dihydrate at a dose of 20 mg/kg, gamma-butyrobetaine at a dose of 20 mg/kg and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts at dose of 20mg/kg were administered p.o. daily for 8 weeks. Control rats received water.

    Isolated rat heart infarction study



    [0032] The isolated rat heart experiment was performed essentially as described earlier (Liepinsh et al., J. Cardiovasc. Pharmacol. 2006; 48(6):314-9). Twenty-four hours after the last drug administration hearts were excised and retrogradely perfused via the aorta at a constant pressure with oxygenated Krebs-Henseleit buffer at 37°C. The heart rate, left ventricle end-diastolic pressure and left ventricle developed pressure were continuously recorded. Coronary flow was measured using an ultrasound flow detector (HSE) and the PowerLab 8 /30 system from ADInstruments. The hearts were perfused for 20 min to stabilize the hemodynamic functions and then occlusion was performed for 60 min by constricting threads through a plastic tube. Successful occlusion was confirmed by a coronary flow decrease of about 40 percent. Reperfusion was achieved by releasing the threads. At the end of the 150-min reperfusion period, the risk zone was delineated with 0.1 % methylene blue. The hearts were then sectioned transversely from the apex to the base in five slices 2 mm in thickness and incubated in 1% triphenyltetrazolium chloride in phosphate buffer (pH 7.4, 37°C) for 10 min to stain viable tissue red and necrotic tissue white. Computerized planemetric analysis of Sony A900 photographs was performed using Image-Pro Plus 6.3 software to determine the area at risk and area of necrosis expressed as a % of the left ventricle. The obtained values were then used to calculate the infarct size (IS) as a % of risk area according to the formula:


    Effects in isolated rat heart infarction model



    [0033] The anti-infarction effect of examined substances was investigated in an isolated rat heart infarction model. During occlusion of left coronary artery, the coronary flow in all experimental groups was decreased for 40% (from 11 ml/min to 7 ml/min). Moreover, the drop of developed left ventricular pressure for 50% was observed. The heart rate during the occlusion period did not change significantly. In reperfusion stage, coronary flow, developed left ventricular pressure, ±dp/dt values were recovered till about 80% of control level. There were no significant differences between control and treatment groups.

    [0034] Effects of Meldonium dihydrate (20 mg/kg), gamma-butyrobetaine (20 mg/kg) and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts (20 mg/kg) after 2 weeks of treatment on infarct size in the isolated rat heart infarction experiment are presented in Table 1, Table 2, Table 3
    Table 1 Effects of Meldonium dihydrate, gamma-butyrobetaine and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate on infarct size
     Infarct size, % of control
    Control 100.0 ±5.9
    Meldonium dihydrate 20 mg/kg 117.9 ±7.9
    Gamma-butyrobetaine 20 mg/kg 87.6 ±11.4
    3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate 20 mg/kg 46.5 ±7.0*,#,$
    Table 2 Effects of Meldonium dihydrate, gamma-butyrobetaine and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate on infarct size
     Infarct size, % of control
    Control 100.0 ±5.9
    Meldonium dihydrate 20 mg/kg 117.9 ±7.9
    Gamma-butyrobetaine 20 mg/kg 87.6 ±11.4
    3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate 20 mg/kg 60.6 ±6.7*,#,$
    Table 3 Effects of Meldonium dihydrate, gamma-butyrobetaine and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate on infarct size
     Infarct size, % of control
    Control 100.0 ±5.9
    Meldonium dihydrate 20 mg/kg 117.9 ±7.9
    Gamma-butyrobetaine 20 mg/kg 87.6 ±11.4
    3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate 20 mg/kg 56.1 ±4.4*,#,$


    [0035] Each values in mentioned Tables from 1-3 represents the mean ± s.e.m. of 9-10 animals.
    *p<0.05 compared with control group; #p<0.05 compared with Gamma-butyrobetaine group, $p<0.05 compared with Meldonium dihydrate group

    [0036] As it is presented in Tables 1-5, Meldonium dihydrate treatment at a dose of 20 mg/kg had no therapeutical effect; gamma-butyrobetaine has decreased infarct size by 12.4 %.

    [0037] Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate at dose of 20 mg/kg decreased infarction size by 53.5 %.

    [0038] 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate at dose of 20 mg/kg decreased infarction size by 39.4 %.

    [0039] 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate at dose of 20 mg/kg decreased infarction size by 43.9 %.


    Claims

    1. Salt of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium, having the general formula
    wherein R1 is -


     
    2. A salt of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium according to claim that is 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate


     
    3. A salt of 3-carboxy-N-ethyl-N,N,dimethylpropan-1-aminium according to claim 1 that is 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate


     
    4. A salt of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium according to claim 1that is 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium dihydrogen phosphate


     
    5. A process for preparing 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt comprising:

    a. adding N,N-dimethylethylamine to ethyl 4-bromobutanoate in appropriate solvent to obtain 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide;

    b. passing 4-ethoxy-N-ethyl-N,N-dimethyl-4-oxo-1-butanaminium bromide through ion exchange resin column to obtain 4-[ethyl(dimethyl)ammonio] butanoate;

    c. adding acid selected from the group, consisting of fumaric acid, orotic acid and phosphoric acid in appropriate solvent to obtain the corresponding 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt.


     
    6. A process according to claim 5, wherein in step a) the appropriate solvent is acetonitrile or acetone.
     
    7. 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt, selected from the group consisting of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate, 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate and dihydrogenphosphate for use as a medicament.
     
    8. 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salt, selected from the group consisting of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium (2E)-3-carboxyacrylate, 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate and dihydrogenphosphate for use in a method of treating cardiovascular diseases.
     
    9. The compound for use according to claim 8, wherein the cardiovascular disease is ischemic heart disease.
     
    10. The compound for use according to claim 9, wherein wherein the ischemic heart disease is myocardial infarction.
     


    Ansprüche

    1. 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminiumsalz weist die folgende allgemeine Formel auf: R1
    Wobei R1
     
    2. Ein Salz aus 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium nach Anspruch 1 ist, das ist
    Salz aus 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium (2E)-3-Carboxyacrylat
     
    3. Ein Salz aus 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium nach Anspruch 1 ist, das ist 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium 2,6 - Dioxo - 1,2,3,6 - Tetra-Hydropyrimidin-4-Carboxylat
     
    4. Ein Salz aus 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium nach Anspruch 1 ist, das ist
    Ein Salz aus 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium Dihydrogenphosphat
     
    5. Ein Verfahren für die Zubereitung von 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminiumsalz, bestehend aus:

    a. Hinzufügen von N,N-Dimethylethylamin zu Ethyl 4 - Bromobutanoat in einem geeigneten Lösungsmittel, um 4-Ethoxy-N-Ethyl-N,N-Dimethyl-4-Oxo-1-Butanaminiumbromid zu gewinnen;

    b. 4-Ethoxy-N-Ethyl-N,N-Dimethyl-4-Oxo-1-Butanaminium- bromid wird durch einen lonenaustausch-Harzbehälter geleitet, um 4-[Ethyl (Dimethyl) Ammonium]-Butanoat zu gewinnen;

    c. Hinzufügen von aus der Gruppe ausgewählten Säuren, bestehend aus Orotsäure und Phosphorsäure in geeignetem Lösungsmittel, um das entsprechende 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminiumsalz zu gewinnen.


     
    6. Ein Verfahren nach Anspruch 5, wobei das geeignete Lösungsmittel in Schritt a) Acetronitril oder Aceton ist.
     
    7. 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminiumsalz, ausgewählt aus der Gruppe 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium (2E)-3 Carboxyacrylat, 2,6-Dioxo-1,2,3,6 - Tetra - Hydropyrimidin-4-Carboxylat und Dihydrogenphosphat, für die Verwendung als Medikament.
     
    8. 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminiumsalz, ausgewählt aus der Gruppe 3-Carboxy-N-Ethyl-N,N-Dimethylpropan-1-Aminium (2E)-3 Carboxyacrylat, 2,6- Dioxo -1,2,3,6 - Tetra - Hydropyrimidin-4-Carboxylat und Dihydrogenphosphat, für die Verwendung als Behandlung von Herz-Kreislauf-Erkrankungen.
     
    9. Verbindung zur Behandlung von
    Gemäß Anspruch 8, wobei Herz-Kreislauf-Erkrankungen durch ischämische Herzerkrankungen ersetzt werden.
     
    10. Verbindung zur Behandlung von
    Gemäß Anspruch 9, wobei ischämische Herzerkrankungen durch Herzinfarkte ersetzt werden.
     


    Revendications

    1. Sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine, en ayant la formule générale Où R1 est -
     
    2. Un sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine selon l'affirmation 1 selon laquelle c'est le (2E)-3-carboxyacrylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine
     
    3. Un sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine selon l'affirmation 1 selon laquelle c'est le 2,6-dioxo-1,2,3,6-tétrahydropyrimidine-4-carboxylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine
     
    4. Un sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine selon l'affirmation 1 selon laquelle c'est le dihydrogénophosphate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine
     
    5. Un processus pour préparer le sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine comprenant :

    a) L'ajout de la N,N-diméthyléthylamine à l'éthyl 4-bromobutanoate dans un solvant approprié pour obtenir le bromure de la 4-éthoxy-N-éthyl-N,N-diméthyl-4-oxo 1-butanamine ;

    b) le passage du bromure de la 4-éthoxy-N-éthyl-N,N-diméthyl-4-oxo 1-butanamine dans une colonne en résine d'échange d'ions pour obtenir le butanoate de 4-[éthyl(diméthyl)ammonium] ;

    c) l'ajout d'un acide sélectionné dans un groupe, constitué par l'acide fumarique, l'acide orotique et l'acide phosphorique dans un solvant approprié pour obtenir le sel correspondant de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine.


     
    6. Un processus selon l'affirmation 5 selon laquelle, où durant l'étape a) le solvant approprié est l'acétonotrile ou l'acétone.
     
    7. Le sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine, sélectionné dans le groupe constitué par le (2E)-3-carboxyacrylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine, le 2,6-dioxo-1,2,3,6-tétrahydropyrimidine-4-carboxylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine et le dihydrogénophosphate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine pour une utilisation comme un médicament.
     
    8. Sel de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine, sélectionné dans le groupe constitué par le (2E)-3-carboxyacrylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine, le 2,6-dioxo-1,2,3,6-tétrahydropyrimidine-4-carboxylate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine et le dihydrogénophosphate de la 3-carboxy-N-éthyl-N,N-diméthylpropane-1-amine pour une utilisation dans une méthode de traitement des maladies cardiovasculaires.
     
    9. Le composé destiné à être utilisé selon l'affirmation 8 selon laquelle la maladie cardiovasculaire est une cardiopathie ischémique.
     
    10. Le composé destiné à être utilisé selon l'affirmation 9 selon laquelle la cardiopathie ischémique est un infarctus du myocarde.
     






    Cited references

    REFERENCES CITED IN THE DESCRIPTION



    This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

    Patent documents cited in the description




    Non-patent literature cited in the description